Obesity is increasingly recognized as an important contributor to asthma severity, with both mechanical and inflammatory mechanisms linked to worse symptoms and more frequent exacerbations. Recently, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as important therapies for obesity management, with growing interest in their potential benefits beyond weight reduction.
In this Q&A, touchRESPIRATORY spoke with Dr Ruchi Patel (Rutgers New Jersey Medical School, Newark, NJ, USA) about the impact of obesity on asthma, the emerging evidence linking GLP-1 receptor agonists with reduced exacerbations, and the key findings and clinical implications of her recent research.
The abstract “Association between Glucagon-Like Peptide-1 Receptor Agonists and Asthma Exacerbations in Non-Diabetic Patients with Obesity: Cohort Study” was presented at AAAAI 2026, Philadelphia, PA, USA; February 27–March 2, 2026. touchRESPIRATORY coverage of AAAAI 2026: Obesity can worsen asthma through both mechanical and inflammatory mechanisms. Excess adipose tissue increases systemic inflammation while also reducing lung volumes and airway compliance, which together can increase asthma symptoms and exacerbation risk. Across overweight, obese, and morbidly obese groups, patients receiving GLP-1 receptor agonists consistently experienced lower asthma exacerbation risk, with relative risk reductions of roughly 20–25%. There was an absolute reduction in exacerbations of about 12–14% over the study period. Our findings suggest GLP-1 therapies may provide additional respiratory benefits for patients with obesity and asthma. The next step will be prospective clinical studies to determine whether these medications directly improve asthma outcomes and to better understand the underlying mechanisms. Already registered? Login below.
Q. How does obesity contribute to increased asthma severity and exacerbations?
Q. What data exists supporting an association between GLP-1 receptor agonists and reduced asthma exacerbations?
Q. Could you describe the aims and methodology of your study using the TriNetX database?
Q. What were the key findings observed across the different BMI categories?
Q. What are the clinical implications of these findings, and what will be the next steps in this research?
Further content in asthma.
Editor: Victoria Smith, Senior Content Editor.
Cite: Beyond weight loss: Could GLP-1 receptor agonists improve asthma outcomes? touchRESPIRATORY. 16 March 2025.
This content has been developed independently by Touch Medical Media for touchRESPIRATORY. It is not affiliated with the American Academy of Allergy, Asthma, and Immunology (AAAAI). Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Related content
- ACAAI 2025: Key highlights in allergy, asthma, and immunology
- EVEREST Trial Reveals Dupilumab’s Superiority Over Omalizumab in CRSwNP with Asthma
- Severe asthma insights: SHARP research on patient-reported outcomes, biologic response, and fatigue
Register now to receive the touchRESPIRATORY newsletter!
Don’t miss out on hearing about our latest peer reviewed articles, expert opinions, conference news, podcasts and more.
